Enterprise Value
40.63M
Cash
57.89M
Avg Qtr Burn
-9.647M
Short % of Float
6.30%
Insider Ownership
4.92%
Institutional Own.
28.08%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
CUE-102 Details Wilms' Tumor 1 (WT1) | Phase 1 Data readout | |
CUE-101 (IL-2) +/- pembrolizumab Details Head and neck cancer, Head and neck squamous cell carcinoma, Cancer, Solid tumor/s, Human papillomavirus | Phase 1 Data readout |